Status:
COMPLETED
Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients
Lead Sponsor:
Nigde Omer Halisdemir University
Conditions:
Postmenopausal Osteoporosis
Eligibility:
FEMALE
45-85 years
Brief Summary
This study, which was designed as a prospective observational study, was planned to enroll 75 female patients with postmenopausal osteoporosis who had been using bisphosphonates for more than two year...
Eligibility Criteria
Inclusion
- Being a woman with postmenopausal osteoporosis
- Being between the ages of 45-85
- Using bisphosphonate therapy for at least two years
- Vertebral and/or Femur T score below -2.5
- Unresponsive to bisphosphonate therapy
- More than 2% decrease in BMD values despite using bisphosphonates and/or
- New major fracture development during treatment
Exclusion
- Male gender
- Being extremely thin (BMI \<15) or extremely obese (BMI\> 45)
- Malignancy
- Severe chronic liver and kidney failure
- Chronic Steroid use
- Having an active rheumatic disease
- Having other secondary causes of osteoporosis (primary hyperparathyroidism etc.).
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2021
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT04702204
Start Date
July 1 2020
End Date
August 15 2021
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Niğde Bor FTR Education and Training hospital
Niğde, Turkey (Türkiye), 51000